Results 151 to 160 of about 8,266,387 (310)

Pulmonary Metastasectomy in Pediatric Solid Tumors

, 2019
Metastatic disease and the complications of treating metastatic disease are the primary causes of mortality in children with solid malignancies. Nearly 25% of children with solid tumors have metastatic disease at initial diagnosis and another 20% develop
Todd E. Heaton, Nicole J. Croteau
core   +1 more source

Solid Cystic Tumors

, 1994
Morphological, ultrastructural and immunophenotypical features of Solid Cystic ...
Morohoshi T, ZAMBONI, Giuseppe, Yamaguchi K   +2 more
core   +1 more source

New guidelines to evaluate the response to treatment in solid tumors

Journal of the National Cancer Institute, 2000
P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan, L. Rubinstein, J. Verweij, M. V. Van Glabbeke, A. V. van Oosterom, M. Christian, S. Gwyther   +10 more
semanticscholar   +1 more source

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source

Neonatal solid tumors

, 2018
Background: Neonatal tumors are different from tumors of the older children and knowledge gained from treating older children can not be extrapolated to neonates. Neonates have immature physiology and their haematopoietic and immune systems are not fully
Aravindan Chandrasekaran
core   +1 more source

Iberverin Downregulates GPX4 and SLC7A11 to Induce Ferroptotic Cell Death in Hepatocellular Carcinoma Cells

Biomolecules
Ferroptosis, a recently elucidated style of regulated cell death, has emerged as a significant area of investigation in cancer biology. Natural active compounds that have anti-cancer effects are promising candidates for cancer prevention.
Haoying Yang, Bolei Dai, Liangjie Chen, Yingping Li, Xiaorui Jin, Chengchang Gao, Linfen Han, Xueli Bian   +7 more
doaj   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

Molecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad, Silvio Carlo Ermanno Tosatto, Emanuela Leonardi   +2 more
wiley   +1 more source

Dendritic Cell-Based Immunotherapy for Solid Tumors

, 2018
As a treatment for solid tumors, dendritic cell (DC)-based immunotherapy has not been as effective as expected. Here, we review the reasons underlying the limitations of DC-based immunotherapy for solid tumors and ask what can be done to improve immune ...
Kwang-Hoe Chung, Nam-Chul Jung, Dae-Seog Lim, Yi Sub Kwak, Jun-Ho Lee   +4 more
core   +1 more source

Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane

npj Breast Cancer
Trastuzumab, pertuzumab, and a taxane (THP) has been the standard first-line therapy for HER2+ advanced breast cancer for over a decade. With new regimens emerging, genomic tools like HER2DX may help identify patients who benefit durably from THP versus ...
Marcin Kubeczko, Sandra Cobo, Rodrigo Sanchez-Bayona, Bartłomiej Pyciński, Jesús Soberino, Ewa Chmielik, Esther Sanfeliu, Maria Rey, Francisco Pardo, Angela Aguirre, Oleguer Castillo, Aleksandra Lesniak, Malgorzata Oczko-Wojciechowska, Esther Carcelero, Barbara Adamo, Maria Vidal, Milana Bergamino, Julia Maues, Guillermo Villacampa, Laia Paré, Patricia Villagrasa, Eva Ciruelos, Aleix Prat, Michal Jarzab, Fara Brasó-Maristany   +24 more
doaj   +1 more source